Narendranath Epperla, MD, MS, FACP

Lymphoma specialist at HCI

[Ajay Major, MD, MBA @majorajay]

NAVD real-world outcomes #lymsm
- 327 pts, med age 37, 24% ≥60 yrs
- ORR 94% (CR 86%)
- 1-yr PFS 94.5%, OS 99.7%
- irAEs in 29% (9% G3+)
- febrile neutropenia 10%, infections 25% (10% G3+)
RW efficacy mirrors S1826, though notably ⬆️ infections (despite GCSF) & irAEs.
https://t.co/YyWRSQxhKu

[Journal of Clinical Oncology @JCO_ASCO]

Five-Year Follow-Up Analysis of ZUMA-5: Axicabtagene Ciloleucel in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma. Co-authored by @JulioChavezMD, @NEpperla, @BachyEmmanuel, @MunshiPashnaMD.

Read the full article. https://t.co/a99Z84FswH
#lymsm #nonhodgkinlymphoma

[Lymphoma Hub @lymphomahub]

CONGRESS | #IACH | PRESENTATION
Naren Epperla @NEpperla @huntsmancancer provides an overview of innovations in the prognostic assessment of patients with lymphoma.
They discuss the prognostic utility of ctDNA by PhaseED-Seq at EOT in patients with 1L DLBCL, the relevance of interim PET after C4 in FL, and the use of prognostic models in EMZL.
Follow our live feed for more updates: https://t.co/iWXsi4pUgU
Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content. A full list of supporters can be found on our website.
#lymphoma #lymsm #MedicalCongress

[Kepecs Lab @KepecsLab]

1/ Why do late-stage cancer patients lose motivation & sink into apathy?
🔥Our new Science paper shows cancer activates a cytokine-sensing brain circuit to lower motivation.Great work by Aelita Zhu @sarahstarosta @Pignatelli_Lab @JanowitzTobias &team!🧵
🔗 https://t.co/j5yD6riRGE

[Roni Shouval @RShouval]

🚨 Just out @NatureMedicine!
Introducing InflaMix—a point-of-care tool that identifies an #inflammatory 🔥 signature predictive of #CART failure in #lymphoma
Led by Sandeep Raj (@SSRaj017) 👏@MSKCancerCenter
https://t.co/k0tQMZBSxS 🧵Let’s break it down

[Muzaffar Qazilbash @Transplant_Doc]

Second primary malignancies following CAR T-cell therapy in patients with hematologic malignancies #mmsm #bmtsm @DrMarcosdelima @NEpperla https://t.co/Bjswz5p0AN

[Nature Reviews Cardiology @NatRevCardiol]

New online! Anthracycline-induced cardiomyopathy: risk prediction, prevention and treatment https://t.co/64DvcaW2SO

[UofU3i @UofU3i]

New 3i Investigator Article Alert!! Impact of circulating lymphoma cells at diagnosis on outcomes in patients with newly diagnosed de novo diffuse large B-cell lymphoma https://t.co/x1bmCPZiVp

[NEJM Evidence @NEJMEvidence]

In this statistical editorial, Larry Han, PhD, reviews the concept of left truncation in time-to-event studies. Read the editorial: https://t.co/aMXFyhq3GE

#ClinicalTrials

[John Vaughn, MD, MS @johnvaughnmd]

Happy to share this new study out in @BloodCancerJnl, coauthored by @NEpperla.

https://t.co/tSn2KgyIES

[Blood Advances @BloodAdvances]

The study shows the safety and long-term efficacy of auto-HCT, even in patients with high-risk cHL who are traditionally considered chemotherapy refractory. https://t.co/4IUaztgybZ #lymphoidneoplasia #transplantation

[Daniel Addison, MD @md_addison]

Cardiac considerations with Emerging Cancer Cellular Therapies:

https://t.co/N1BerfxfvP

Thanks @BloodAdvances for publishing this work.

Excellent work by @MalakMunirMD @ASayedMD @NEpperla

#cardioonc #cancer #leukemia #lymphoma

[Abhishek Lenka @AbhiLenka11]

Exciting discovery: CSF flow isn't confined to the brain and spinal cord—it also extends to peripheral nerves! @ScienceMagazine https://t.co/pgjYciGqvR

Groundbreaking research from @UFHealth @UF
#neurotwitter #neuroscience #AcademicChatter

[John Vaughn, MD, MS @johnvaughnmd]

https://t.co/KJtS5mNukl

[Ajay Major, MD, MBA @majorajay]

Multicenter CNS involvement in HGBL NOS @NEpperla:
- 160 pts, 7% baseline CNSi
- CNSi➡️MYC-R, testicular/female pelvic
- no diff in PFS/OS for CNSi vs not (2-yr PFS 53-55%)
- 11% CNS relapse at 3 years
- mOS 6-7 mos at relapse regardless of CNSi #lymsm
https://t.co/zSPzTHlDbC

[Andrew M. Evens, DO, MBA, MSc @DrAEvens]

We are looking forward to working on this more- adding ⬆️ cases & analyses (45-49% vs <45% split was arbitrary but may be relevant).

Much more work in this area is needed as these #lymphoma pts are often excluded from clinical trials.

@NEpperla @DrRaulCordoba #ASH23 #CardioOnc

[Dr. Patrick Hwu @PatrickHwuMD]

#ScienceSaturday Can dietary nutrients help the immune system kill #cancer cells? In this study, researchers screened 255 circulating nutrients for the ability to enhance T cell activity and found that the long-chain fatty acid TVA (Trans-vaccenic acid) could enhance the activity of CD8-positive “killer” T cells against cancer. This impressive work has significant implications for cancer #immunotherapy and beyond.

Here’s a link to the full article. https://t.co/avfwOVZV8k

[Uriel Suárez @UsuarezMD]

Impact of circulating lymphoma cells at diagnosis on outcomes in patients with marginal zone lymphoma: a multicenter cohort study | Blood Advances | American Society of Hematology https://t.co/ddUfPvFHGI

[Eddie Cliff @Eddie_Cliff]

#ASH23 Late breaking abstract 2

The long-awaited SYMPATICO trial

Ibr+Ven vs Ibr+pbo RCT in R/R MCL
- med PFS 31.9 vs 22.1 months, HR 0.65 p = 0.005
- median OS 44.9 vs 38.6 mo (not significant)

https://t.co/ZDHrGMb0Sx h/t @dgermain21 #lymsm